Apogee Therapeutics Inc
APGE
Company Profile
Business description
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Contact
221 Crescent Street
Building 17, Suite 102b
WalthamMA02453
USAT: +1 650 394-5230
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
261
Stocks News & Analysis
stocks
Undervalued wide moat share may be overlooked
A series of negative updates dulls sentiment in wide moat share.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,160.30 | 13.70 | -0.15% |
| CAC 40 | 8,297.57 | 4.28 | -0.05% |
| DAX 40 | 25,874.05 | 96.06 | -0.37% |
| Dow JONES (US) | 52,766.88 | 419.02 | -0.79% |
| FTSE 100 | 10,760.63 | 28.65 | -0.27% |
| HKSE | 25,311.21 | 18.52 | -0.07% |
| NASDAQ | 26,099.77 | 271.12 | -1.03% |
| Nikkei 225 | 64,325.64 | 1,889.70 | -2.85% |
| NZX 50 Index | 13,930.57 | 143.67 | 1.04% |
| S&P 500 | 7,631.47 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,978.40 | 1.80 | -0.02% |
| SSE Composite Index | 3,941.39 | 38.50 | -0.97% |